This site is intended for healthcare professionals
News

DURECT Corporation announces the outcome of the FDA Advisory Committee meeting for Posimir which resulted in a split vote on the treatment of post-surgical pain .

Read time: 1 mins
Published:19th Jan 2020
DURECT Corporation has announced that the (FDA Anesthetic and Analesic Drug Products Advisory Committee (AADPAC) met to discuss the Class 2 New Drug Application (NDA) resubmission for Posimir (bupivacaine extended-release solution). In a split vote on the key question, six advisory committee members voted to recommend that the efficacy, safety, and overall risk-benefit profile of PosimirR support approval, while six did not support approval based on the information presented. Although the FDA considers the recommendations of the AADPAC, the recommendations by the panel are non-binding. The final decision regarding pending regulatory actions for a product is made by the FDA.
Condition: Pain:Post Surgical
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.